Accuray Incorporated (ARAY)
NASDAQ: ARAY · Real-Time Price · USD
2.240
-0.060 (-2.61%)
Jan 17, 2025, 4:00 PM EST - Market closed
Accuray Revenue
Accuray had revenue of $101.55M in the quarter ending September 30, 2024, a decrease of -2.26%. This brings the company's revenue in the last twelve months to $444.20M, down -2.37% year-over-year. In the fiscal year ending June 30, 2024, Accuray had annual revenue of $446.55M, down -0.24%.
Revenue (ttm)
$444.20M
Revenue Growth
-2.37%
P/S Ratio
0.50
Revenue / Employee
$450,055
Employees
987
Market Cap
225.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 446.55M | -1.05M | -0.24% |
| Jun 30, 2023 | 447.61M | 17.70M | 4.12% |
| Jun 30, 2022 | 429.91M | 33.62M | 8.48% |
| Jun 30, 2021 | 396.29M | 13.36M | 3.49% |
| Jun 30, 2020 | 382.93M | -35.86M | -8.56% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
ARAY News
- 7 days ago - Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System - PRNewsWire
- 13 days ago - Accuray - There's Value If Linac Sales Accelerate, But That's A Big 'If' - Seeking Alpha
- 4 weeks ago - New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat - PRNewsWire
- 7 weeks ago - Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules - PRNewsWire
- 2 months ago - Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Accuray Reports Fiscal 2025 First Quarter Financial Results - PRNewsWire
- 3 months ago - Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024 - PRNewsWire
- 3 months ago - Accuray Appoints Michael Murphy as VP, Corporate Controller - PRNewsWire